2019 International Congress

Monday, September 23, 2019

1:45pm-3:15pm

Increasing chances of detecting a neuroprotective signal in PhI/II PD clinical trials?

S. Palfi, C. Denot, A. Bousseau, JC. Corvol (Paris, France)

Clinical Trials, Pharmacology and Treatment  ·  Agora 3 West, Level 3

1:45pm-3:15pm

Inflammatory cytokines in Saudi Parkinson cohort

N. Alsomali, E. Al-Ofi, M. Obaid, A. Alrafiah (Riyadh, Saudi Arabia)

Other  ·  Agora 2 West, Level 2

1:45pm-3:15pm

Influence of baseline OFF-time in the efficacy response of Parkinson’s disease patients with motor fluctuations: post-hoc analysis from combined BIPARK-I and II

A. Santos, J. Ferreira, A. Lees, H. Reichmann, W. Poewe, F. Ikedo, D. Magalhães, J. Rocha, P. Soares-da-Silva (Coronado, Portugal)

Clinical Trials, Pharmacology and Treatment  ·  Agora 3 West, Level 3

1:45pm-3:15pm

Influence of demographic characteristics in the efficacy response of Parkinson’s disease patients with motor fluctuations: post-hoc analysis from combined BIPARK-I and II.

A. Santos, J. Ferreira, A. Lees, H. Reichmann, W. Poewe, F. Ikedo, D. Magalhães, J. Rocha, P. Soares-da-Silva (Coronado, Portugal)

Clinical Trials, Pharmacology and Treatment  ·  Agora 3 West, Level 3

1:45pm-3:15pm

Influence of disease duration in the efficacy response of Parkinson’s disease patients with motor fluctuations: post-hoc analysis from combined BIPARK-I and II

H. Gama, J. Ferreira, A. Lees, A. Antonini, O. Rascol, A. Santos, D. Magalhães, J. Rocha, P. Soares-da-Silva (Coronado, Portugal)

Clinical Trials, Pharmacology and Treatment  ·  Agora 3 West, Level 3

1:45pm-3:15pm

Influence of disease severity in the efficacy response of Parkinson’s disease patients with motor fluctuations: post-hoc analysis from combined BIPARK-I and II

H. Gama, A. Lees, J. Ferreira, O. Rascol, A. Antonini, A. Santos, D. Magalhães, J. Rocha, P. Soares-da-Silva (Coronado, Portugal)

Clinical Trials, Pharmacology and Treatment  ·  Agora 3 West, Level 3

1:45pm-3:15pm

Influence of motor fluctuations duration, levodopa dose and duration of use in efficacy responses of Parkinson’s disease patients: post-hoc analysis from combined BIPARK-I and II.

A. Santos, A. Lees, J. Ferreira, O. Rascol, A. Antonini, F. Ikedo, D. Magalhães, J. Rocha, P. Soares-da-Silva (Coronado, Portugal)

Clinical Trials, Pharmacology and Treatment  ·  Agora 3 West, Level 3

1:45pm-3:15pm

Inhibition of mitochondrial complexes induces unique transcriptomic and epigenetic profiles: implications to neurodegeneration induced movement disorders

R. Sathyanarayanan, S. Bharath (Bangalore, India)

Other  ·  Agora 2 West, Level 2

1:45pm-3:15pm

Inpatient vs outpatient workup of patients with ataxia and suspected paraneoplastic cerebellar degeneration: Does work-up location matter?

N. Witek, M. Afshari, Y. Liu, B. Ouyang, D. Hall (Chicago, IL, USA)

Ataxia  ·  Les Muses, Level 3

1:45pm-3:15pm

Insomnia as clinical onset symptom in Juvenile Huntington’s Disease: Evaluation of a Family

M. Gultekin (Kayseri, Turkey)

Huntington’s Disease  ·  Agora 3 West, Level 3